TY - JOUR
T1 - Protein S-100B
T2 - A serum marker for ischemic and infectious injury of cerebral tissue
AU - Bertsch, Thomas
AU - Casarin, Wendy
AU - Kretschmar, Marianne
AU - Zimmer, Wilma
AU - Walter, Silke
AU - Sommer, Clemens
AU - Muehlhauser, Frank
AU - Ragoschke, Andreas
AU - Kuehl, Sandra
AU - Schmidt, Roland
AU - Pohlmann-Eden, Bernd
AU - Nassabi, Claudius
AU - Nichterlein, Thomas
AU - Faßbender, Klaus
N1 - Funding Information:
We gratefully acknowledge the support of grants from the Fakultät für Klinische Medizin Mannheim (KLIMA) 69 (1995) and the Deutsche Forschungsgemeinschaft (DFG) KR 2002 / 1-1
PY - 2001
Y1 - 2001
N2 - The S-100B protein is released by injured astrocytes. After passage through a disintegrated blood-brain barrier (BBB) the molecule can be detected in the peripheral circulation. We investigated the association between the extent of brain injury and S-100B concentration in serum in cerebral injury caused by cerebral ischemia and cerebral fungal infection. Study I: The S-100B serum concentration was serially determined in 24 patients with ischemic stroke at 4, 8, 10, 24, 72 hours after the onset of symptoms. We observed that patients with brain lesions larger than 5 cm3 exhibited significantly increased serum levels of S-100B at 10, 24 and 72 hours compared to those with lesion volumes below 5 cm3. Furthermore, an association between S-100B serum concentration and neurological outcome was observed. Study II: In a mouse model of systemic fungal infection with Candida albicans we observed that serum levels of S-100B increased at day 1 after intravenous infection. At this time we could histologically demonstrate brain tissue injury by invading hyphae which had crossed the BBB. Furthermore, reactive astrogliosis was demonstrated by immunohistochemistry. On day 7 we found a significant decrease of S-100B serum level compared to day 1 and 4. This was associated with a demarcation of the fungi with leukocytes in brain tissue at this late phase of infection. No further invasion through the BBB was seen on day 7. In conclusion, serum levels of S-100B reflect the time course of tissue injury in cerebral ischemia and cerebral infection to a similar extent. Thus, S-100B may be a useful marker to assess cerebral tissue injury.
AB - The S-100B protein is released by injured astrocytes. After passage through a disintegrated blood-brain barrier (BBB) the molecule can be detected in the peripheral circulation. We investigated the association between the extent of brain injury and S-100B concentration in serum in cerebral injury caused by cerebral ischemia and cerebral fungal infection. Study I: The S-100B serum concentration was serially determined in 24 patients with ischemic stroke at 4, 8, 10, 24, 72 hours after the onset of symptoms. We observed that patients with brain lesions larger than 5 cm3 exhibited significantly increased serum levels of S-100B at 10, 24 and 72 hours compared to those with lesion volumes below 5 cm3. Furthermore, an association between S-100B serum concentration and neurological outcome was observed. Study II: In a mouse model of systemic fungal infection with Candida albicans we observed that serum levels of S-100B increased at day 1 after intravenous infection. At this time we could histologically demonstrate brain tissue injury by invading hyphae which had crossed the BBB. Furthermore, reactive astrogliosis was demonstrated by immunohistochemistry. On day 7 we found a significant decrease of S-100B serum level compared to day 1 and 4. This was associated with a demarcation of the fungi with leukocytes in brain tissue at this late phase of infection. No further invasion through the BBB was seen on day 7. In conclusion, serum levels of S-100B reflect the time course of tissue injury in cerebral ischemia and cerebral infection to a similar extent. Thus, S-100B may be a useful marker to assess cerebral tissue injury.
UR - http://www.scopus.com/inward/record.url?scp=17744399719&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=17744399719&partnerID=8YFLogxK
U2 - 10.1515/CCLM.2001.050
DO - 10.1515/CCLM.2001.050
M3 - Article
C2 - 11388656
AN - SCOPUS:17744399719
SN - 1434-6621
VL - 39
SP - 319
EP - 323
JO - Clinical Chemistry and Laboratory Medicine
JF - Clinical Chemistry and Laboratory Medicine
IS - 4
ER -